Genelux

GNLXPhase 3

Genelux is pioneering a novel class of oncolytic virotherapies based on its proprietary, genetically modified vaccinia virus platform. The company's lead asset, Olvi-Vec, is in Phase 2/3 development for platinum-resistant/refractory ovarian cancer, with data suggesting potential for improved survival and immune activation. Genelux's strategy centers on demonstrating the efficacy of its platform as a monotherapy and in combination with other immunotherapies to address significant unmet needs in oncology.

Market Cap

$107.3M

Employees

11-50

Focus

Biotech

GNLX · Stock Price

USD 2.403.75 (-60.98%)

Historical price data

AI Company Overview

Technology Platform

Proprietary platform of genetically modified vaccinia virus (VACV) strains engineered for selective oncolytic activity and induction of systemic anti-tumor immunity.

Pipeline Snapshot

10 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin (preferred) or ...	Platinum-resistant Ovarian Cancer	Phase 3
Olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin or cisplatin + ...	Advanced Non-squamous Non-small-cell Lung Cancer	Phase 2
Olvi-Vec + platinum (cisplatin or carboplatin) + Etoposide	SCLC, Extensive Stage	Phase 1/2
GL-ONC1	Peritoneal Carcinomatosis	Phase 1/2
GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab	Ovarian Cancer	Phase 1/2

Opportunities

The primary opportunity is the successful development and approval of Olvi-Vec for platinum-resistant ovarian cancer, a high-need area with limited options.

The vaccinia virus platform also offers expansion potential into other solid tumors and combination regimens with checkpoint inhibitors, representing a broad pipeline opportunity.

Risk Factors

Key risks include clinical trial failure, regulatory rejection, significant ongoing financial losses requiring dilutive capital raises, and intense competition in the oncology immunotherapy space from both approved drugs and other oncolytic virus platforms.

Competitive Landscape

Genelux competes with Amgen's approved Imlygic and other clinical-stage oncolytic viruses from companies like DNAtrix, Replimune, and Oncolytics Biotech. Its differentiation lies in its vaccinia virus platform, which allows for systemic delivery potential and a strong immunogenic profile.